Istradefylline for Parkinson's Disease with Cognitive Impairment
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this research study is to determine whether istradefylline improves cognition in individuals with Parkinson disease with cognitive impairment.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it requires that your antiparkinsonian medications and cholinesterase inhibitor doses are stable for a certain period before starting the trial.
Is istradefylline safe for humans?
Istradefylline has been studied for safety in people with Parkinson's disease, and common side effects include dizziness, constipation, nausea, hallucinations, and trouble sleeping. It is generally considered safe when used with other Parkinson's treatments, but more studies are needed to understand its long-term effects.12345
How is the drug Istradefylline unique for treating Parkinson's disease with cognitive impairment?
Istradefylline is unique because it works by blocking a specific brain receptor (adenosine A2A) to help reduce 'OFF' time in Parkinson's patients, which is when symptoms return between medication doses. It is also noted for having fewer side effects, making it suitable for patients with cognitive issues or depression.34567
What data supports the effectiveness of the drug istradefylline for Parkinson's Disease with Cognitive Impairment?
Who Is on the Research Team?
Matthew Barrett, MD
Principal Investigator
Virginia Commonwealth University
Are You a Good Fit for This Trial?
This trial is for individuals over 50 with Parkinson's disease who are experiencing cognitive impairment. They must be in the early to moderate stages of the disease, taking carbidopa/levodopa, and have stable medication doses. Those with dementia related to Lewy bodies, severe liver issues, or women who could become pregnant aren't eligible.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive usual care and take istradefylline daily for 26 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Istradefylline
Istradefylline is already approved in United States, Japan for the following indications:
- Parkinson's disease
- Parkinson's disease
Find a Clinic Near You
Who Is Running the Clinical Trial?
Virginia Commonwealth University
Lead Sponsor
Kyowa Kirin, Inc.
Industry Sponsor